-
Most Popular
Search Results
240 results for MER
Capital Destruction Paves Way for Further Losses
Once in a lifetime events are piling up so fast that we are going to need several lifetimes to absorb them. Someday we’ll look back…
Will the Support Hold?
Our indicators and charts are telling us that the market is testing its support at Dow 8,000 and S&P 500 800.
Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated
Novavax stock offers a unique opportunity to invest in a late stage biotech built on cutting-edge vaccine technology, NVAX stock has surged on its Covid-19…
Merck Could Be the Covid-19 Investment You’re Missing
Some traders consider Merck stock to be a safe Dow Jones type of investment. Yet, the Covid-19 vaccine angle could propel the share price.
Novavax Stock Looks Like It’s a Solid Bet on a Coronavirus Vaccine
While it’s no guarantee that NVAX stock will be the ultimate winner from a Covid-19 vaccine, investors should pay attention to Novavax.
Without Positive Vaccine News, Novavax May Fall Further
NVAX stock is likely to stay under further pressure until it can release more positive clinical data
Moderna Faces Tough Threats in the Short and Long Term
Moderna is facing meaningful short-term and longer-term threats. As a result, investors should sell MRNA stock at this point.
If You Like Alibaba Stock, these 3 ETFs Make Perfect Sense
While Alibaba stock is enticing, you may want to consider ETFs that have meaningful exposure to it. That way, if something goes wrong, your entire…
Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild
NVAX stock has been among the hottest stocks in 2020, but it still remains a risky investment
Why Science and Economics Might Justify CureVac
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust…
Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing
With White House health advisor Dr. Anthony Fauci’s endorsement of Gilead Sciences’ remdesivir, INO stock now seems irrelevant. But that might not be accurate if…
5 Weird Mutual Funds Worth Your Investment
Most mutual funds use some kind of industry-standard stock selection methodology. A few like to do their own thing. Here are four worth considering.
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
NVAX stock’s prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate
As Optimism Wanes, the Ride May Be Over for Novavax stock
Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up…
I Would Hope Inovio Isn’t Attracting ANY Serious Money
A recent article wondered if the smart money preferred Ocugen or Inovio. I would hope neither INO stock or OCGN is getting any serious money.
Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
Germany Makes a $299 Million Bet on CureVac
CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?
As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating
INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks…
Is Inovio Stock Still a Buy After Its Massive 150% Leap This Year?
Inovio is developing a potential vaccine for the coronavirus. If you can handle the volatility, it may be time to buy INO stock.
7 – 10 of 240 results
